BofA analyst Michael Ryskin raised the firm’s price target on Waters (WAT) to $375 from $370 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Waters Corporation Amends Credit Agreement for Flexibility
- Waters Corporation Re-elects Board at Annual Meeting
- Waters Corporation’s Strategic Acquisition of Halo Labs: Enhancing Biologics Capabilities and Market Position
- Waters acquires Halo Labs
- Waters price target raised to $370 from $350 at BofA
